EGFR/B7H3 CAR-T (Bio-gene Technology)

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameEGFR/B7H3 CAR-T (Bio-gene Technology)
Drug Alias NameEGFR/B7H3 CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-CD276
TargetsEpidermal growth factor receptor erbB1CD276 antigen
Therapy Area/IndicationsLung NeoplasmsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSecond Affiliated Hospital Of Guangzhou Medical UniversityGuangzhou Bio-Gene Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Guangzhou Medical UniversityGuangzhou Bio-Gene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A